Does the media prefer INCY or MIRM?

In the previous week, Incyte had 2 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 10 mentions for Incyte and 8 mentions for Mirum Pharmaceuticals. Incyte's average media sentiment score of 0.75 beat Mirum Pharmaceuticals' score of 0.62 indicating that Incyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incyte 3 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mirum Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor BNTX or MIRM?

In the previous week, BioNTech had 21 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 29 mentions for BioNTech and 8 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 0.62 beat BioNTech's score of 0.14 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 12 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Mirum Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MIRM or UTHR?

In the previous week, United Therapeutics had 15 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 23 mentions for United Therapeutics and 8 mentions for Mirum Pharmaceuticals. United Therapeutics' average media sentiment score of 0.65 beat Mirum Pharmaceuticals' score of 0.62 indicating that United Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive United Therapeutics 13 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MIRM or GMAB?

In the previous week, Genmab A/S had 4 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 12 mentions for Genmab A/S and 8 mentions for Mirum Pharmaceuticals. Genmab A/S's average media sentiment score of 0.64 beat Mirum Pharmaceuticals' score of 0.62 indicating that Genmab A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Genmab A/S 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MIRM or ASND?

In the previous week, Ascendis Pharma A/S had 15 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 23 mentions for Ascendis Pharma A/S and 8 mentions for Mirum Pharmaceuticals. Ascendis Pharma A/S's average media sentiment score of 0.68 beat Mirum Pharmaceuticals' score of 0.62 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Ascendis Pharma A/S 7 Very Positive mention(s) 7 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Mirum Pharmaceuticals (MIRM) Competitors

$91.83 -6.99 (-7.07%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$92.88 +1.05 (+1.14%)

As of 09/18/2026 07:30 PM Eastern

Compare

MIRM vs. INCY, BNTX, UTHR, GMAB, and ASND

Should you buy Mirum Pharmaceuticals stock or one of its competitors? Mirum Pharmaceuticals's main competitors and comparable companies include Incyte (INCY), BioNTech (BNTX), United Therapeutics (UTHR), Genmab A/S (GMAB), and Ascendis Pharma A/S (ASND). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Mirum Pharmaceuticals compare to Incyte?

Incyte (NASDAQ:INCY) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation, media sentiment and analyst recommendations.

Incyte has a beta of 0.77, indicating that its stock price is 23% less volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.49, indicating that its stock price is 51% less volatile than the broader market.

In the previous week, Incyte had 2 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 10 mentions for Incyte and 8 mentions for Mirum Pharmaceuticals. Incyte's average media sentiment score of 0.75 beat Mirum Pharmaceuticals' score of 0.62 indicating that Incyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incyte	3 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mirum Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Incyte presently has a consensus target price of $124.05, suggesting a potential downside of 1.01%. Mirum Pharmaceuticals has a consensus target price of $137.31, suggesting a potential upside of 49.53%. Given Mirum Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Mirum Pharmaceuticals is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incyte	0 Sell rating(s)	13 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.52
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

Incyte has a net margin of 27.71% compared to Mirum Pharmaceuticals' net margin of -139.18%. Incyte's return on equity of 29.93% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incyte	27.71%	29.93%	22.88%
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%

97.0% of Incyte shares are owned by institutional investors. 16.2% of Incyte shares are owned by insiders. Comparatively, 8.3% of Mirum Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Incyte has higher revenue and earnings than Mirum Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incyte	$5.14B	4.94	$1.29B	$7.85	15.96
Mirum Pharmaceuticals	$521.31M	11.44	-$23.36M	-$14.55	N/A

Summary

Incyte beats Mirum Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

How does Mirum Pharmaceuticals compare to BioNTech?

BioNTech (NASDAQ:BNTX) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, media sentiment, dividends, institutional ownership and profitability.

BioNTech has a beta of 1.29, suggesting that its share price is 29% more volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.49, suggesting that its share price is 51% less volatile than the broader market.

15.5% of BioNTech shares are held by institutional investors. 19.2% of BioNTech shares are held by insiders. Comparatively, 8.3% of Mirum Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

BioNTech has a net margin of -63.54% compared to Mirum Pharmaceuticals' net margin of -139.18%. BioNTech's return on equity of -6.86% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-63.54%	-6.86%	-6.00%
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%

Mirum Pharmaceuticals has lower revenue, but higher earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	7.48	-$1.29B	-$7.83	N/A
Mirum Pharmaceuticals	$521.31M	11.44	-$23.36M	-$14.55	N/A

In the previous week, BioNTech had 21 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 29 mentions for BioNTech and 8 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 0.62 beat BioNTech's score of 0.14 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	12 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Mirum Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

BioNTech currently has a consensus target price of $126.00, indicating a potential upside of 31.17%. Mirum Pharmaceuticals has a consensus target price of $137.31, indicating a potential upside of 49.53%. Given Mirum Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Mirum Pharmaceuticals is more favorable than BioNTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	5 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.68
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

Summary

BioNTech beats Mirum Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Mirum Pharmaceuticals compare to United Therapeutics?

Mirum Pharmaceuticals (NASDAQ:MIRM) and United Therapeutics (NASDAQ:UTHR) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, media sentiment, institutional ownership, valuation, profitability and risk.

94.1% of United Therapeutics shares are held by institutional investors. 8.3% of Mirum Pharmaceuticals shares are held by insiders. Comparatively, 8.6% of United Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Mirum Pharmaceuticals presently has a consensus price target of $137.31, suggesting a potential upside of 49.53%. United Therapeutics has a consensus price target of $646.00, suggesting a potential upside of 30.60%. Given Mirum Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Mirum Pharmaceuticals is more favorable than United Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85

Mirum Pharmaceuticals has a beta of 0.49, meaning that its share price is 51% less volatile than the broader market. Comparatively, United Therapeutics has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market.

United Therapeutics has a net margin of 41.56% compared to Mirum Pharmaceuticals' net margin of -139.18%. United Therapeutics' return on equity of 20.18% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%
United Therapeutics	41.56%	20.18%	17.98%

In the previous week, United Therapeutics had 15 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 23 mentions for United Therapeutics and 8 mentions for Mirum Pharmaceuticals. United Therapeutics' average media sentiment score of 0.65 beat Mirum Pharmaceuticals' score of 0.62 indicating that United Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
United Therapeutics	13 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

United Therapeutics has higher revenue and earnings than Mirum Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	11.44	-$23.36M	-$14.55	N/A
United Therapeutics	$3.18B	6.67	$1.33B	$27.95	17.70

Summary

United Therapeutics beats Mirum Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does Mirum Pharmaceuticals compare to Genmab A/S?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Genmab A/S (NASDAQ:GMAB) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability, media sentiment and institutional ownership.

7.1% of Genmab A/S shares are held by institutional investors. 8.3% of Mirum Pharmaceuticals shares are held by company insiders. Comparatively, 1.5% of Genmab A/S shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Mirum Pharmaceuticals presently has a consensus price target of $137.31, indicating a potential upside of 49.53%. Genmab A/S has a consensus price target of $39.50, indicating a potential upside of 13.70%. Given Mirum Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Mirum Pharmaceuticals is more favorable than Genmab A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Genmab A/S	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85

Mirum Pharmaceuticals has a beta of 0.49, suggesting that its share price is 51% less volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.84, suggesting that its share price is 16% less volatile than the broader market.

Genmab A/S has higher revenue and earnings than Mirum Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	11.44	-$23.36M	-$14.55	N/A
Genmab A/S	$3.72B	5.83	$963M	$1.27	27.35

Genmab A/S has a net margin of 19.08% compared to Mirum Pharmaceuticals' net margin of -139.18%. Genmab A/S's return on equity of 14.89% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%
Genmab A/S	19.08%	14.89%	7.73%

In the previous week, Genmab A/S had 4 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 12 mentions for Genmab A/S and 8 mentions for Mirum Pharmaceuticals. Genmab A/S's average media sentiment score of 0.64 beat Mirum Pharmaceuticals' score of 0.62 indicating that Genmab A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Genmab A/S	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Genmab A/S beats Mirum Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Mirum Pharmaceuticals compare to Ascendis Pharma A/S?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Ascendis Pharma A/S (NASDAQ:ASND) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation.

Mirum Pharmaceuticals has a beta of 0.49, meaning that its share price is 51% less volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.35, meaning that its share price is 65% less volatile than the broader market.

Ascendis Pharma A/S has a net margin of 70.99% compared to Mirum Pharmaceuticals' net margin of -139.18%. Ascendis Pharma A/S's return on equity of 32.54% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%
Ascendis Pharma A/S	70.99%	32.54%	7.71%

In the previous week, Ascendis Pharma A/S had 15 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 23 mentions for Ascendis Pharma A/S and 8 mentions for Mirum Pharmaceuticals. Ascendis Pharma A/S's average media sentiment score of 0.68 beat Mirum Pharmaceuticals' score of 0.62 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascendis Pharma A/S	7 Very Positive mention(s)	7 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Mirum Pharmaceuticals currently has a consensus target price of $137.31, suggesting a potential upside of 49.53%. Ascendis Pharma A/S has a consensus target price of $310.75, suggesting a potential upside of 31.27%. Given Mirum Pharmaceuticals' higher probable upside, research analysts plainly believe Mirum Pharmaceuticals is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	3.00

Mirum Pharmaceuticals has higher earnings, but lower revenue than Ascendis Pharma A/S. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	11.44	-$23.36M	-$14.55	N/A
Ascendis Pharma A/S	$814.57M	18.13	-$258M	$12.89	18.36

Summary

Ascendis Pharma A/S beats Mirum Pharmaceuticals on 11 of the 14 factors compared between the two stocks.

Get Mirum Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MIRM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MIRM vs. The Competition

Export

Metric	Mirum Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.42B	$3.92B	$7.24B	$13.14B
Dividend Yield	N/A	3.65%	2.57%	12.30%
P/E Ratio	-6.31	14.30	275.79	25.40
Price / Sales	11.44	1,415.50	695.58	114.44
Price / Cash	1,938.44	110.75	77.42	51.66
Price / Book	15.00	15.45	10.46	6.33
Net Income	-$23.36M	-$22.86M	$3.49B	$358.33M
7 Day Performance	-6.51%	-1.21%	0.59%	1.12%
1 Month Performance	-10.18%	-4.42%	-2.01%	-2.67%
1 Year Performance	23.46%	37.81%	18.09%	6.01%

Mirum Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MIRM Mirum Pharmaceuticals	3.0443 of 5 stars	$91.83 -7.1%	$137.31 +49.5%	+21.9%	$6.42B	$521.31M	N/A	433	Gap Up High Trading Volume
INCY Incyte	3.346 of 5 stars	$126.01 +1.3%	$124.05 -1.6%	+45.7%	$25.22B	$5.14B	16.05	2,844
BNTX BioNTech	4.3572 of 5 stars	$98.13 -0.5%	$126.00 +28.4%	-0.3%	$24.95B	$3.25B	N/A	7,807	Analyst Forecast Insider Trade
UTHR United Therapeutics	4.2811 of 5 stars	$506.82 +1.8%	$646.00 +27.5%	+20.7%	$21.36B	$3.18B	18.13	1,400	Insider Trade
GMAB Genmab A/S	4.2675 of 5 stars	$33.04 -1.5%	$39.50 +19.6%	+23.9%	$20.92B	$3.72B	26.02	3,029	Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MIRM) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mirum Pharmaceuticals (MIRM) Competitors

MIRM vs. INCY, BNTX, UTHR, GMAB, and ASND

How does Mirum Pharmaceuticals compare to Incyte?

Summary

How does Mirum Pharmaceuticals compare to BioNTech?

Summary

How does Mirum Pharmaceuticals compare to United Therapeutics?

Summary

How does Mirum Pharmaceuticals compare to Genmab A/S?

Summary

How does Mirum Pharmaceuticals compare to Ascendis Pharma A/S?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MIRM vs. The Competition

Mirum Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mirum Pharmaceuticals (MIRM) Competitors

MIRM vs. INCY, BNTX, UTHR, GMAB, and ASND

How does Mirum Pharmaceuticals compare to Incyte?

Which has more volatility and risk, INCY or MIRM?

Does the media prefer INCY or MIRM?

Do analysts prefer INCY or MIRM?

Is INCY or MIRM more profitable?

Do insiders & institutionals hold more shares of INCY or MIRM?

Which has stronger valuation and earnings, INCY or MIRM?

Summary

How does Mirum Pharmaceuticals compare to BioNTech?

Which has more risk and volatility, BNTX or MIRM?

Do insiders & institutionals have more ownership in BNTX or MIRM?

Is BNTX or MIRM more profitable?

Which has preferable valuation & earnings, BNTX or MIRM?

Does the media favor BNTX or MIRM?

Do analysts recommend BNTX or MIRM?

Summary

How does Mirum Pharmaceuticals compare to United Therapeutics?

Do institutionals & insiders believe in MIRM or UTHR?

Do analysts recommend MIRM or UTHR?

Which has more volatility & risk, MIRM or UTHR?

Is MIRM or UTHR more profitable?

Does the media prefer MIRM or UTHR?

Which has stronger earnings and valuation, MIRM or UTHR?

Summary

How does Mirum Pharmaceuticals compare to Genmab A/S?

Do insiders and institutionals have more ownership in MIRM or GMAB?

Do analysts recommend MIRM or GMAB?

Which has more volatility and risk, MIRM or GMAB?

Which has stronger valuation & earnings, MIRM or GMAB?

Is MIRM or GMAB more profitable?

Does the media refer more to MIRM or GMAB?

Summary

How does Mirum Pharmaceuticals compare to Ascendis Pharma A/S?

Which has more risk & volatility, MIRM or ASND?

Is MIRM or ASND more profitable?

Does the media prefer MIRM or ASND?

Do analysts recommend MIRM or ASND?

Which has better valuation & earnings, MIRM or ASND?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MIRM vs. The Competition

Mirum Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools